Rosetta Genomics, Israeli Medical Center to Develop miRNA Assay for CAD | GenomeWeb

NEW YORK (GenomeWeb News) — Rosetta Genomics said today that it is collaborating with Clalit Health Services' Rabin Medical Center-Beilinson Campus to develop a non-invasive, microRNA-based assay to diagnose chronic allograft dysfunction (CAD) following kidney transplantation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.